Altruist Biologics Secures NMPA Priority Review for Localized Biologic Drug Manufacturing

COMPANY PROFILE
  • Altruist Biologics has secured acceptance and priority review from China’s National Medical Products Administration (NMPA) for a new drug application covering the localized manufacturing of a biologic drug developed by a multinational pharmaceutical company.
  • The company’s Hangzhou facility has a planned total antibody manufacturing capacity of 172,000 liters, with 80,000 liters currently operational.

Altruist Biologics, a contract development and manufacturing organization (CDMO) and wholly owned subsidiary of Innovent Biologics, has received notification that China’s National Medical Products Administration (NMPA) has accepted a new drug application (NDA) and granted priority review for the localized manufacturing of a biologic drug developed by a multinational pharmaceutical company. The designation is expected to shorten the regulatory review timeline and support an accelerated pathway toward approval.

The application marks a step in the client’s transition from overseas manufacturing to domestic production in China. Altruist said its partnership with the multinational company established a localized manufacturing pathway using its end-to-end capabilities and expertise in NMPA regulatory requirements. The arrangement follows China’s introduction of a regulatory framework for manufacturing localization in 2024.

Altruist’s Hangzhou facility is designed with a total antibody manufacturing capacity of 172,000 liters. Of this capacity, 80,000 liters are currently operational across four 20,000-liter stainless-steel bioreactors. A 2,000-liter single-use production line is under construction and is expected to become operational by mid-2027.

The site also houses a standalone antibody-drug conjugate (ADC) and AXC bioconjugation facility. It supports the manufacture of various bioconjugates, including high-potency ADCs, for clinical and commercial supply at small and large scales. The company said its Hangzhou operations meet Good Manufacturing Practice (GMP) requirements across major regulatory authorities.

“The successful NDA acceptance and priority review are the result of close team collaboration between Altruist and our valued partner. Localizing manufacturing offers global companies an opportunity to strengthen supply chain resilience, while expanding access to innovative medicines for patients in China.”

Dr. Kaisong Zhou, Chairman and CEO of Altruist Biologics
EXCLUSIVE DOWNLOAD

Download the full CDMO Live Report for 112 pages of insights and best practices in external manufacturing.